Lyon, France— May 2016 – Mapi Research Trust, the leading curator and license distributor of Clinical Outcome Assessments (COAs) will present two posters at the Annual Meeting of the American Society of Clinical PsychoPharmacology (ASCP, formerly ECDEU and NCDEU)
• The translatability of psychiatric terms with the example of the Mini-International Neuropsychiatric Interview (M.I.N.I.), a project developed and presented in collaboration with Dr David Sheehan
• Results of a review of guidance documents and authorizations of medicinal products on the role of Clinical Outcome Assessment (COA) data in the drug approval process of products for the treatment of autism spectrum disorder in the USA and Europe
Mapi Research Trust, as the largest single COA licensing provider and the most trusted name in distribution of COA instruments exclusively representing over 250 questionnaires, will take this opportunity to share its experience in psychiatric disorders through the availability of renown specific rating scales and their translations distributed by Mapi Research Trust on behalf of their developers and copyright holders in this domain e.g. the Hamilton Depression and Anxiety scales, the Hospital Anxiety and Depression Scale (HADS), the Neuropsychiatric Inventory (NPI), the Mini-International Neuropsychiatric Interview (M.I.N.I. 6.0), and many others.
>> To learn more about Mapi or should you be interested in meeting at the ASCP conference in Scottsdale (AZ) from May 31st to June 3rd, please contact Marie-Pierre Emery, Senior Author Relations Specialist at Mapi Research Trust: firstname.lastname@example.org
About Mapi Research Trust:
The Mapi Research Trust is a Non-Profit arm of Mapi Group and works in collaboration with Academic Researchers, Life-Science Companies and Regulatory bodies. It is the largest curator of Clinical Outcomes Assessments (COA) and their translations, the largest single COA licensing provider and the most trusted name in distribution of COA instruments exclusively representing over 250 questionnaires.
Mapi Group has over 40 years of experience supporting Life-Science companies in utilizing Patient Reported Outcomes measures, Health Research Language Services, Value communications and Commercialization support, Strategic Regulatory Services, and gathering Real-World Evidence on Pharmaceuticals, Biologicals, and Medical devices. Mapi Group is the premier provider of Health Research and Commercialization services to Life-Science companies enabling Market Authorization, Market Access and Market Adoption of novel therapeutics. Visit http://www.mapigroup.com for more information.
Press contact: Media@mapigroup.com